Target intelligence / Profile preview

Plasmepsin IV

Molecular classification: Enzyme, Aspartic protease, Peptidase family A1

Overview

Plasmepsin IV is an essential digestive enzyme enabling malaria parasites to degrade host hemoglobin inside red blood cells—a process crucial for their survival and proliferation. Its unique structure among plasmodial enzymes makes it highly conserved yet sufficiently different from human enzymes, supporting its candidacy as a selective antimalarial drug target.

Mechanism of action

Inhibition of hemoglobin degradation

Biological functions

Hemoglobin degradationProtein processingNutrient acquisition

Disease associations

InfectionMalaria

Safety considerations

Potential off-target effects if drugs are not selective enough

Beyond the preview

Go deeper on Plasmepsin IV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmepsin IV.

Explore the full profile